God is our Guide  Number 1 site for help

  

CIDPUSA.ORG

 
Home
Diagnosis
Treatment
Pathology
Variants
F.A.Q
Fibromyalgia
IVIG
Diet anti-inflammatory
Burning  Feet Home
Services Page
Chronic Fatigue
Autoimmune diseases
Prognosis
Bible healing
Celiac disease

Women Heart Disease

  Natural Makeup
  Neck Pain
  Ocular Female diseases
  Chronic fatigue syndrome
  Osteoporosis
  Women Heart Attacks
  Breast Size & Disease
  Breast massage
  PARKINSON
 Memory problems
  Breast Lymph Drainage
  Kidney stone Buster
 Bras cause breast cancer
Skin repair Clinic
 Pandas
  Hepatitis

 Under active thyroid

Iodine deficiency china

Women & Thyroid

Thyroid is ageing you

Autoimmune  Thyroid

Thyroid & Myasthenia

Hashimotos

Thyroiditis

Grave Disease

Oparas disease

Goiter

Autoimmune self attack

New Psoriasis Rx

Turmeric & arthritis

Soccer arthritis

IgA nephropathy Fish oil

Behcet Disease

Takayasu

 Pandas

Inner Ear Disease AIED

Risk of heart disease & stroke 

Depression and breast cancer

rheumatoid arthritis

Nail Fungus

SESAME SEED OIL

Facial  cleaner

oil pulling

 Reading disorders

 

 Graves Disease-II

   alternatives treatment of all disease please read our e-book 

GRAVES' DISEASE

 

Special GoogleHealth Search

What is Gravesí disease?

Harefuah. 2001 May;140(5):392-4, 455, 454., Links

[Intravenous immunoglobulins treatment of patients with Graves' ophthalmopathy]   Leibe A, Levy Y, Shoenfeld Y.Sheba Medical Center,  Tel-Aviv Univ

Graves' ophthalmopathy is an autoimmune disease manifested as exophthalmus, lid lag and diplopia. As in the accompanying autoimmune thyroid disease, there is an autoimmune homonal and cellular attack on the orbita, mainly the retro-orbital tissues. Steroids are the cornerstone of therapy. We reviewed the evidence for a similar therapeutic effect of i.v., immunoglobulins (IVIGs) and their better side affect profile as compared to steroids. We also described an impressive therapeutic success with IVIG given to a patient with resistant ophthalmopathy. The clinical picture of Graves' ophthalmopathy is attributed to a pathologic hyper--activation of orbital fibroblasts, deposition of collagen and glycosaminoglycans in the extra-cellular matrix and eventually fibrosis. These are mediated by leucoregulin, IL-1, IFN-gamma, and TGF-beta--all secreted by lymphocytes and mast cells in the retorbital space. Another mode of cell activation is by binding of autoantibodies (presumably thyroid stimulating Ab's) to an antigenic determinant on the surface of fibroblasts. I.v. immunoglobulins, known today to be active in a variety of autoimmune processes, exert their effect on autoantibodies, complement, phagocytic cells etc. IVIGs also inhibit orbital lymphocytes and fibroblasts through inhibition of IL-1 or/and TGF-beta.

Thyroid. 1997 Aug;7(4):579-85.

Intravenous immunoglobulin versus corticosteroid in treatment of Graves' ophthalmopathy.

Baschieri L, Antonelli A, Nardi S, Alberti B, Lepri A, Canapicchi R, Fallahi P.

Institute of Clinical Medicine II, University of Pisa, Italy.

We compared the effectiveness of systemic corticosteroids with the use of high-dose intravenous immunoglobulin (IVIG) in the treatment of Graves' ophthalmopathy. This was performed as a prospective, nonrandomized study including a blinded ophthalmological and orbital computed tomographic (CT) evaluation. The two groups of patients were not significantly different in relation to sex composition, age distribution, duration of Graves' disease, and ophthalmopathy and previous hyperthyroidism. All patients were followed up by endocrinologic evaluation and blinded ophthalmological (before therapy = B, at the end of therapy = E, and 6 months after the end = 6M) and orbital CT (B and E) evaluations. Twenty-seven patients treated with IVIG were followed up after the end of treatment for an average of 21 months (range 12 to 48 months). Soft tissue involvement (NOSPECS) improved or disappeared in 32 of 35 (90%) patients treated with IVIG and in 25 of 27 (92.5%) patients treated with corticosteroids. Diplopia improved or disappeared in 22 of 29 (75%) patients treated with IVIG and in 16 of 20 (80%) patients treated with corticosteroids.



 

 The results observed by clinical evaluation were confirmed with orbital CT score in 30 IVIG patients and in the corticosteroid-treated patients; a significant reduction of extraocular muscle thickness was observed after treatment in both groups. Proptosis improved or disappeared in 20 of 31 (65%) patients treated with IVIG and in 15 of 24 (62%) patients treated with corticosteroids. Mean values of proptosis evaluated by Hertel's exophthalmometer showed a slight reduction both in IVIG as well as in corticosteroid-treated patients. It is interesting to observe that in 28 IVIG-treated patients in whom it was possible to evaluate soft tissue involvement, proptosis and diplopia in the period between the fifth and sixth month from the start of therapy, the most important part of the amelioration (if responders) was already obtained at that time. Responder patients were defined in relation to the decrease in the highest NOSPECS class or grade. Among IVIG-treated patients 26 of 34 (76%) responded; while in the corticosteroid group 18 of 27 (66%) responded to treatment. The prevalences of patients who responded to the treatments were not significantly different in the two groups (Chi-square). The initial values of the subjective eye score were similar in the two groups, and a significant reduction was observed in both. Major side effects requiring discontinuation of the corticosteroid therapy were observed in two patients with hemorrhagic gastritis and in one patient with manic-depressive psychosis. Among 15 patients submitted to the evaluation of bone mineral content before and after corti-costeroid therapy, 4 presented signs of osteoporosis and 3 a reduction of bone mineral content. Moderate and minor side effects were more frequently noted in steroid-treated patients than in the IVIG group. These data suggest that IVIG is safe and effective in reducing the eye changes in patients with Graves' ophthalmopathy.

PMID: 9292946 [PubMed - indexed for MEDLINE]

 

 

Please go to the next page Human Brainneurotransmitter page